SQZ Biotech Signs Lease at Arsenal Yards

Boston –  Boylston Properties, a Boston-based real estate developer, announced that cell therapy company SQZ Biotech has signed a 63,477sf lease at Arsenal Yards. With 200,000sf of lab and office space, Arsenal Yards is meeting the demand from the life science community for lab space in the East End of Watertown.

Arsenal Yards is being developed by Boylston Properties, Wilder, and J.P. Morgan.

The new lab space is set within an original 1800’s Arsenal historic building, with soaring 25 foot ceilings, multiple boutique fitness operators, dedicated parking, and a private shuttle to Harvard Square. It is across the street from LINX, 185,000sf of new fully-leased lab space completed in 2018, also developed by Boylston Properties.

SQZ Biotech recently completed a $72 million Series C and expanded a clinical and commercial development collaboration with Roche. The young life science company will dramatically increase its footprint when it relocates from its current Watertown location to Arsenal Yards later this year. Utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies, SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune disease.

Located on the Charles River in the dynamic East End neighborhood of Watertown, Arsenal Yards will be a thriving urban village with over 50 retailers & restaurants including Roche Bos. and the seven screen Majestic Theater, over 300 contemporary residences, a 150-room Hampton Inn & Suites by Hilton, as well as office and life sciences space. The development will also include considerable open spaces throughout, access to a revitalized Arsenal Park, as well as connection to the Watertown-Cambridge multi-use bike path.